About Invengene
Invengene is a Healthcare company based in Mumbai (India) founded in 2023. It provides RD, manufacturing, and commercialization services for pharmaceuticals worldwide. It operates on a B2B model. Its Indian entity Invengene Private Limited reported revenue of ₹11.75 Cr. Invengene offers products and services including R&D Services, Manufacturing Services, and Commercialization Services. Its focus areas include Biotechnology, Pharmaceuticals, Drug Delivery and Manufacturing.
Company details
Invengene delivers comprehensive pharmaceutical services, including research and development, manufacturing, and business development, focusing on drug delivery technologies like injectables. The company partners with global entities to bridge portfolio gaps in emerging and regulated markets, ensuring efficient scaling and regulatory compliance. Based in India, it supports clients from product ideation to market launch with a skilled team.
- Headquarters Mumbai, India
- SectorsHealthcare
- Email••••••••
- Website invengene.com
- Social LinkedIn
- Legal Name Invengene Private Limited
- Date of Incorporation 02 Aug, 2023
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹11.75 Cr
FY 2025
- Net Loss-₹16.49 Cr
FY 2025 · -140% margin
- EBITDA-₹13.09 Cr
FY 2025 · -111% margin
Associated legal entities of Invengene
Invengene operates through Invengene Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Invengene Private Limited CIN U21002MH2023PTC407959 | Active | 02 Aug 2023 | Mumbai, Maharashtra | ₹11.8 Cr | 35 | 6 | View details |
Products & Services of Invengene
Invengene offers a comprehensive portfolio of products and services, including R&D Services, Manufacturing Services, and Commercialization Services.
Offers ideation and development for pharmaceutical products
Handles scale-up and manufacturing of injectables
Manages regulatory filing and market launch strategies
Board of directors of Invengene Private Limited (Invengene)
Invengene Private Limited is the primary company behind Invengene. The board of Invengene Private Limited currently have 6 directors; the longest-serving is Janak Ramanlal Shah, appointed in 2023. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Janak Ramanlal Shah DIN 00019819 | Individual Subscriber | 02 Aug 2023 | 3 yrs 2 mo | Invengene Private Limited |
| Maya Janak Shah DIN 00019904 | Individual Subscriber | 02 Aug 2023 | 3 yrs 2 mo | Invengene Private Limited |
| Rajat Vishal Shah DIN 05346532 | Individual Subscriber | 02 Aug 2023 | 3 yrs 2 mo | Invengene Private Limited |
| Ankur Janak Shah DIN 01656781 | Whole-time director | 02 Aug 2023 | 3 yrs 2 mo | Invengene Private Limited |
| Vishal Janak Shah DIN 05349303 | Individual Subscriber | 02 Aug 2023 | 3 yrs 2 mo | Invengene Private Limited |
| Vaibhavi Ankur Shah DIN 03592009 | Whole-time director | 02 Aug 2023 | 3 yrs 2 mo | Invengene Private Limited |
People of Invengene
2 people are tracked at Invengene (1 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
| Director | Leadership | |
Pratik Redkar | Lead Manager - Corporate Communications | Team |
Complete people profiles for Invengene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Invengene
Figures of Invengene Private Limited, the primary company behind Invengene, for FY 2025. Revenue was ₹11.75 Cr. Net loss was -₹16.49 Cr (-140% margin). EBITDA was -₹13.09 Cr (-111% margin).
- ₹11.75 CrRevenue · FY 2025
- -₹16.49 CrNet loss · -140% margin
- -₹13.09 CrEBITDA · -111% margin
- ₹1.51 CrPaid-up capital
- 35Employees (provident fund records)
Balance sheet, profit and loss, cash flow and ratios of Invengene Private Limited are on its company page.
Detailed financial statements for Invengene
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Invengene (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Invengene
Complete news archive for Invengene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Invengene
Invengene was founded in 2023.
Invengene is headquartered in Mumbai, India. It is registered at Mumbai, Maharashtra, India.
The primary company behind Invengene, Invengene Private Limited, reported revenue of ₹11.75 Cr for FY 2025.
Invengene delivers comprehensive pharmaceutical services, including research and development, manufacturing, and business development, focusing on drug delivery technologies like injectables. The company partners with global entities to bridge portfolio gaps in emerging and regulated markets, ensuring efficient scaling and regulatory compliance. Based in India, it supports clients from product ideation to market launch with a skilled team.
Invengene offers R&D Services, Manufacturing Services, and Commercialization Services.
Invengene operates through Invengene Private Limited.
The legal entities of Invengene currently have 6 directors, including Janak Ramanlal Shah, Maya Janak Shah, Rajat Vishal Shah and others.